Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs)

Authors :: Laura Galli
U. De Giorgi
Riccardo Ricotta
G. Tonini
Sebastiano Buti
Maurizio Nicodemo
Matteo Santoni
Elena Verzoni
G. Procopio
C. Porta
Francesco Massari
Marco Maruzzo
Alessandro Conti
Piero Marchetti
Bruno Vincenzi
G. Di Lorenzo
Daniele Santini
Elisa Biasco
D. De Lisi
Stefano Cascinu
Source :: Journal of Clinical Oncology. 33:e15594-e15594
Publication Year :: 2015
Publisher :: American Society of Clinical Oncology (ASCO), 2015.
Abstract: e15594 Background: Data about complete remission in patient with metastatic mRCC in TKIs era are extremely limited. We performed a multicenter, retrospective analysis of patients who obtained CR du...

Tools